PSILAdvisorShares Psychedelics ETF

Grow my money4y track recordRanked #2,336 of 2,960 in this goal

Seeks long-term capital appreciation.

By AdvisorShares · Launched 2021

Annual Cost

1.00%

#4,954 of 5,562 · expensive

Fund Size

$37M

#3,839 of 5,562 · small

Return (1Y)Goal

+55.4%

Track Record

4 years

#2,464 of 5,562 · seasoned

Performance

Total-return NAV · USD

Growth of $10,000

$14,663+46.6%

Total-return NAV, USD. Net of fund fees, before tax.

Classification

How Beacon categorizes this fund

Asset class

Equity

Strategy

Active selection

Focus

Biotech & Genomics

What it actually holds

By weight

Concentration

Top 10 holdings = 80.6% of fundconcentrated

DREY INST PREF GOV MM-MDSVXX

17.8%

Atai Beckley NV

12.1%

Compass Pathways Plc

8.6%

Relmada Therapeutics Inc

8.4%

Supernus Pharmaceuticals Inc

7.6%

Mind Medicine MindMed Inc

7.5%

NRX Therapeutics Inc

4.8%

Alkermes PLC

4.6%

GH Research PLC

4.6%

Neurocrine Biosciences Inc

4.5%

Asset allocation

Stocks

99.3%

Bonds

0.7%

By sector

Healthcare

100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years

Volatility (1Y)

42.4%High

Year-on-year price swings

Max drawdown

-92.7%Severe

Worst peak-to-trough loss

Sharpe (3Y)

0.33Below average

Sortino (3Y)

0.77Moderate downside risk

Where to buy

Listing

Exchange: NYSE Arca

Full fund details

Objective: Seeks long-term capital appreciation.
Strategy: Actively invests primarily in publicly listed life sciences companies focused on psychedelic medicines and related activities. Includes U.S. and foreign mid-, small-, and micro-cap equity securities, and may use total return swaps for exposure. Concentrates at least 25% in the pharmaceuticals, biotechnology & life sciences industry.
Inception date: September 15, 2021
Fund family: AdvisorShares